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Abstract 21 
Background: An accumulation of international evidence demonstrates that pharmacist prescribing is effective, 22 
safe and well-accepted. While there is potential for such development in the Middle East, the majority of 23 
published studies are largely reported from Western countries and the perspectives of individuals in strategic 24 
positions of policy and practice in the Middle East were unknown. 25 
Objective: To explore the views of key stakeholders in Qatar regarding the potential development and 26 
implementation of pharmacist prescribing. 27 
Methods: Qualitative, face-to-face semi-structured interviews were conducted with stakeholders in strategic 28 
positions of policy influence (i.e. medical, pharmacy and nursing department directors, health-related 29 
academics, patient safety and quality directors, professional regulators). Stakeholders were recruited via 30 
purposive and snowball sampling. The interview schedule was constructed from an extensive literature review 31 
and grounded in the Consolidated Framework for Implementation Research (CFIR) to ensure comprehensive 32 
exploration of potential facilitators and barriers. Interviews were conducted from April to August 2017, digitally 33 
recorded, transcribed, and independently analysed by two researchers using CFIR as a coding framework.  34 
Results: Thirty-seven interviews were conducted with directors of medicine (n=5), pharmacy (n=6) and nursing 35 
(n=5), healthcare policy developers (n=6), healthcare academics (n=9), and patient safety advocates (n=6). 36 
Interviewees were aware of pharmacist prescribing models internationally and generally supported development 37 
and implementation in Qatar due to perceived benefits of improved patient care, professional development and 38 
enhanced team working. While there were more facilitators than barriers, it was clear that there was a 39 
requirement to systematically plan the development and implementation of pharmacist prescribing, with 40 
reference to all five CFIR domains. The need for further training, demonstration of pharmacists’ prescribing 41 
competence, and extensive engagement of stakeholders were considered crucial.  42 
Conclusion: There is potential for pharmacist prescribing to be developed and implemented in Qatar. Further 43 
research is warranted to define the models of prescribing suitable for Qatar, and to highlight issues of education, 44 
training and accreditation.  45 
Keywords: prescribing, clinical pharmacy, implementation, pharmacist, Qatar  46 
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Introduction 47 
Prescribing by pharmacists has been implemented in several countries including the United Kingdom (UK), 48 
United States of America (USA), Canada, and New Zealand.1 While the specific prescribing legislation varies 49 
from country to country, the three main models are independent prescribing, supplementary prescribing, and 50 
collaborative prescribing.2 According to the UK Department of Health (2006), the aims of non-medical 51 
prescribing (i.e. prescribing by suitably qualified health professionals other than doctors and dentists) in the UK 52 
are to: improve patient care without compromising patient safety, make it easier for patients to get the medicines 53 
they need, increase patient’s choice in accessing medicines, make better use of the skills of healthcare 54 
professionals, and contribute to the introduction of more flexible team working across the National Health 55 
Service.3 56 
There is increasing evidence of the effectiveness and safety of pharmacist prescribing derived from systematic 57 
reviews and meta-analyses.4 A Cochrane review of 46 studies (37,337 participants) of prescribing by 58 
pharmacists (20 studies) and nurses (26 studies) compared to medical prescribing was conducted.5 It concluded 59 
that pharmacist and nurse prescribers, practising with varying but high levels of prescribing autonomy, in a 60 
range of settings, were as effective as usual care by medical prescribers for a range of acute and chronic 61 
conditions.5 A more recent systematic review of pharmacist prescribing compared to medical prescribing in the 62 
hospital setting (15 studies) reported equivalent or improved outcomes for blood pressure, cholesterol, glucose, 63 
anticoagulation, satisfaction, and medication adherence.6 Stakeholders’ views and experiences of pharmacist 64 
prescribing implementation have also been consistently positive, as reported in a systematic review of 65 65 
studies.7 Twenty-nine studies were conducted prior to implementation, 35 post-implementation, and one was 66 
conducted both pre- and post-implementation of pharmacist prescribing. The overwhelming findings of this 67 
review were encouraging, particularly in relation to increased access to healthcare services, perceptions of 68 
improved patients’ outcomes, better utilisation of pharmacists’ skills and knowledge, improved job satisfaction, 69 
and reduced physicians’ workload. Concerns were largely identified pre-implementation and were around 70 
organisational issues and perceived lack of pharmacists’ diagnosis skills.7 One limitation of the studies included 71 
in this review was that all were conducted in the Western world; hence, the findings may not be generalisable or 72 
transferable to other regions with differing healthcare systems, ethnicity, culture, and work practices. 73 
Furthermore, none of the studies applied implementation theory to the research design, data collection or 74 
analysis hence may not have comprehensively captured all relevant factors. There was also a paucity of 75 
qualitative studies hence a lack of depth and richness of findings.7 76 
The need to consider theory in developing and implementing interventions such as pharmacist prescribing is 77 
articulated in the UK Medical Research Council (MRC) Framework for Developing and Evaluating Complex 78 
Interventions.8 According to this framework, a new model of prescribing would be considered a ‘complex 79 
intervention’ given the number of groups and organisational levels affected, the degree of behaviour change 80 
required and the number and variability of outcomes. Embedding implementation theory throughout the 81 
development and implementation stages is likely to lead to more effective, efficient, and sustained change 82 
compared to a more pragmatic approach.9 The Consolidated Framework for Implementation Research (CFIR) 83 
was developed in an attempt to simplify the selection of the most appropriate implementation theory from the 84 
multitude of theories, many of which have different terminologies, are often overlapping, and lack one or more 85 
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key elements. CFIR is a synthesis of 18 published models, theories, and frameworks that facilitate translation of 86 
research findings into practice.10, 11 Figure 1 summarises the five CFIR domains which can positively or 87 
negatively influence implementation: characteristics of innovation being implemented into a particular 88 
organisation, outer setting (economical, political, and social context within which an organisation resides), inner 89 
setting (structural, political, and cultural context through which implementation process will proceed), 90 
characteristics of individuals involved, and process of implementation.10, 11 CFIR may, therefore, enable a more 91 
comprehensive consideration of key issues related to the development and implementation of pharmacist 92 
prescribing.  93 
 94 
Figure 1: CFIR domains 95 
The State of Qatar, a peninsula situated halfway along the western coast of the Arabian Gulf, has had the highest 96 
gross domestic product (GDP) per capita globally for the past 10 years.12 Over this period, Qatar has taken 97 
action to transform the healthcare system (Figure 2) in order to achieve better patient care outcomes for current 98 
and future generations, as outlined in its National Vision 2030 and National Health Strategy. One aim is to 99 
establish “a comprehensive world-class healthcare system”, with emphasis on shifting care from secondary and 100 
tertiary settings to primary care and better utilise the skilled and motivated workforce, including pharmacists.13-101 
16 There is, hence, the potential to embed pharmacist prescribing within healthcare settings in Qatar. This study 102 
aimed to explore the views of key stakeholders on the potential of developing and implementing pharmacist 103 
prescribing in Qatar.  104 
 105 
Figure 2: Healthcare system in Qatar 106 
 107 
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Methods 109 
Study design 110 
A qualitative approach was selected in an attempt to obtain in-depth perspectives key stakeholders. Semi-111 
structured interviews were chosen over focus groups for several reasons including the desire to obtain individual 112 
rather than collective views and the logistical difficulties of scheduling focus groups with high profile 113 
participants. 114 
Settings 115 
Data generation took place in Qatar, across all major organisations and institutions relating to the practice, 116 
education, regulation and governance of pharmacists. These comprised of the Ministry of Public Health 117 
(MoPH); primary, secondary, and tertiary healthcare settings; community pharmacies; and all healthcare 118 
academic institutions providing medicine, nursing, pharmacy, and pharmacy technician education programmes 119 
in Qatar. 120 
Inclusion and exclusion criteria 121 
The intention was to generate data representing all key stakeholder groups in Qatar, including experts in their 122 
respective fields with policy influence relating to the development and implementation of models of care. The 123 
groups targeted were individuals in key strategic positions of policy influence “(i.e. medical, pharmacy and 124 
nursing department directors, health-related academics, patient safety and quality directors, professional 125 
regulators). These stakeholders were recruited from: the Ministry of Public Health; the largest governmental 126 
hospital group; the largest governmental and private primary healthcare settings; the different governmental and 127 
private academic healthcare institutes; and the largest private community pharmacy chains. 128 
Sampling and sample size 129 
The sampling frame included all individuals meeting the inclusion and exclusion criteria. Names and contact 130 
details were collated by the research team members based in Qatar, using their professional networks. Purposive 131 
sampling, representing diversity of years of experience and country of professional training, was adopted. This 132 
allowed identifying and approaching those individuals most likely to contribute to the achievement of the 133 
research aim and provide valuable insight through multiple perspectives. In addition, snowball sampling was 134 
also used to ensure that no key individuals had been omitted, by asking each interviewee to recommend others 135 
that they thought important to include. Recruitment continued to the likely point of data saturation for each 136 
stakeholder group (i.e. the point at which no new themes emerged).17 137 
Interview schedule development 138 
The semi-structured interview schedule was drawn from a comprehensive literature review, an umbrella review 139 
of systematic reviews on non-medical prescribing and the systematic review of views and experiences 140 
conducted by the research team.4, 7 CFIR10 was incorporated into the interview schedule to ensure 141 
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comprehensive coverage of key factors related to development and implementation of pharmacist prescribing. 142 
The schedule was reviewed for credibility by members of the research team prior to piloting with five healthcare 143 
academic and practice-based stakeholders, who were subsequently excluded from the dataset. No changes were 144 
made based following the pilot interviews hence these were included as part of the dataset. An overview of the 145 
interview schedule questions and alignment to the research questions and CFIR are presented in Table 1.  146 
Table 1: Semi-structured interview key questions 
Research questions Related theory constructs Interview questions 
What are stakeholders’ 
awareness, experiences and 
views of prescribing by non-
medical health professionals 
with a focus on pharmacists? 
Intervention Characteristics Are you aware of the possibility of prescribing 
by health professionals other than physicians? 
What are stakeholders’ views 
and perceptions of clinical roles 
of pharmacists in Qatar? 
Inner Setting How do you feel about current 
programs/practices/process that are available 
related to current clinical pharmacist roles in 
Qatar? 
What are stakeholders’ views 
and perceptions of expanding 
the remit of pharmacists in 
Qatar to include prescribing? 
All 5 domains What do you think about implementing 
pharmacist prescribing in Qatar? 
Inner Setting Do you think implementing pharmacist 
prescribing will meet the health needs of the 
Qatari community? 
What are the stakeholders’ 
views and perceptions of 
facilitators, barriers and 
solutions to the development 
and implementation of 
pharmacist prescribing in 
Qatar? 
Process What kind of changes or alterations do you 
think will need to be made to successfully 
implement pharmacist prescribing in Qatar? 
Outer Setting How do you think patients will respond to 
pharmacist prescribing? 
Inner Setting and Characteristics of 
Individuals 
How confident do you think your colleagues 
feel about implementing the intervention? 
Inner Setting To what extent might the implementation take 
a backseat to other high-priority initiatives 
going on now? 
Inner Setting Do you expect to have sufficient resources to 
implement and administer the intervention? 
Data generation 147 
From April to August 2017, all potential stakeholders were invited via email to participate and provided with 148 
detailed study information. If agreeing, a convenient location, date and time for interview was negotiated. 149 
Interviews of approximately 45-60 minutes were conducted by a trained researcher with a background in 150 
pharmacy. Probes, such as ‘can you tell me more about that’ and ‘what did you mean when you said…’ were 151 
used throughout the interviews to obtain detailed responses and explanations. Interviews were digitally audio-152 
recorded and transcribed verbatim as soon as possible following completion of the interview. All interviewees 153 
were offered the opportunity to review the transcripts to promote credibility and dependability.18  154 
Data analysis 155 
Thematic analysis was conducted according to the steps outlines by Howitt.19 On completion of transcribing, all 156 
interviews were input into NVivo® software. Initial coding was as per CFIR constructs followed by 157 
identification and definition of emerging themes under each construct. Each theme was then characterised as a 158 
facilitator or a barrier to development and implementation. The analysis was independently conducted by two 159 
researchers (TJ and one other), with any disagreements resolved through discussion.  160 
 161 
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Ethical considerations 162 
Ethical approval was received from Robert Gordon University (RGU) School of Pharmacy & Life Sciences 163 
Research Ethics Committee (Approval reference S64), Ministry of Public Health (MoPH) Ethics Committee, 164 
Hamad Medical Corporation (HMC) Medical Research Committee (Approval reference MRC0449/2017), and 165 
Qatar University (QU) Institutional Review Board (Approval reference QU-IRB 772-E/17). Written, informed 166 
consent was obtained from all research participants before commencing the interviews. 167 
Results 168 
Stakeholder recruitment 169 
Data saturation was deemed to have been achieved in each stakeholder group after 37 interviews had been 170 
completed. Stakeholder groups and details of interviewees are presented in Table 2.  171 
Table 2: Characteristics of included stakeholders according to practice setting 
Stakeholder category Setting: Number of interviewees 
Academic leaders • Medicine: 2 
• Pharmacy and Pharmacy technician: 5 
• Nursing: 2 
Healthcare policy developers • Primary care/Community: 1 
• Secondary care: 1 
• Tertiary care: 2 
• Corporate/Ministry: 2 
Medical practice leaders • Secondary care: 2 
• Tertiary care: 3 
Pharmacy practice leaders • Primary care/Community: 2 
• Secondary care: 1 
• Tertiary care: 2 
• Corporate/Ministry: 1 
Nursing practice leaders • Secondary care: 1 
• Tertiary care: 2 
• Corporate/Ministry: 2 
Patient safety advocates • Primary care/Community: 1 
• Secondary care: 1 
• Tertiary care: 4 
Themes 172 
The themes identified, mapped to CFIR domains and constructs, are summarised in Table 3. In general, there 173 
were no marked differences in responses from interviewees across the professional groupings.   174 
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Table 3: A summary of the CFIR domains and constructs relating to views and perspectives on pharmacist prescribing in Qatar 
CFIR 
domain 
CFIR constructs Themes Illustrative quotes 
In
no
va
tio
n 
ch
ar
ac
te
ri
st
ic
s 
Innovation source 
Many of the interviewees across all stakeholder groups were aware of the 
concept of non-medical, and specifically pharmacist, prescribing. 
“Worldwide, there are different and many models of prescribing. So there is the North American model 
which is usually in most cases more of a collaborative framework… In the UK they started a decade or 
two ago to have independent prescribing models for both nurses and pharmacists… But even many other 
countries have started to do that.” 
 Healthcare Policy Leader 2 
Several were, however, less aware of non-medical prescribing practice. “I am not sure actually. Where I come from in Germany or Switzerland that is not the case. In the United 
States, I think it is the case but I don’t know to what extent.”                            Medical Practice Leader 1 
Interviewees highlighted that this was not currently within scope of 
practice in Qatar. 
“They will advise the doctor that this is right or you need to modify… But not a direct dealing with 
prescribing.”                                                                                                      Patient Safety Advocate 2 
There was recognition of the new role within anticoagulation which 
required physicians’ co-signatures. 
“I only know at Heart Hospital, they have anticoagulation clinic where the pharmacists are involved… I 
think they are recommending the doses and the doctors will agree.”                Academic Leader 4 
Evidence strength and 
quality 
Most considered the evidence around this initiative of sufficient quantity 
and strength to support developments in other countries. 
“Pharmacist prescribing privileges in the UK… has been established since long time and there is also 
enough data to show the effectiveness and the efficiency of such initiative.”   Academic Leader 3 
Relative 
advantage 
There were particular advantages to the pharmacists themselves by 
increasing their job satisfaction and confidence. 
“It will increase their self-confidence, they will feel that they are able to contribute more to society, they 
will feel that they are really a valued member of the healthcare team.”            Academic Leader 1 
There were benefits for physicians, with reduced time spent on 
prescribing. 
“This will also reduce the pressure that we put on the physicians.”                  Academic Leader 3 
It could lead to more timely access to care and improved patient 
satisfaction. 
“That would also enhance the patient experience itself in terms of waiting time, quick access to 
healthcare professionals.”                                                                                  Healthcare Policy Leader 2 
Pharmacist prescribers could be more effective and safer than physicians 
given their education and training on medication. 
“When I look at the data we currently have, there is definitely room for improvement… I think having 
people who are specifically trained and experienced in that area has got to be better.” 
Healthcare Policy Leader 5 
This has also the potential for reducing the cost of healthcare. “When you make the physicians’ time available for more complicated cases, this may be associated with 
cost reduction.”                                                                                                   Academic Leader 3 
It could also impact the roles and responsibilities of pharmacy 
technicians. 
“I know pharmacy technicians will obviously have more responsibilities because the pharmacists will 
have to spend time with the patients.”                                                                Academic Leader 4 
The image of the profession may also improve resulting in increased 
applications to study pharmacy in Qatar. 
“Having privileges for pharmacists to prescribe medications will really help in improving the pharmacy 
picture in the community… It will help in recruiting more national pharmacists.”      
                                                                                                                            Academic Leader 3 
Trialability Another key theme was the need to start slowly by piloting in defined 
areas prior to implementing on a wider scale. 
“I would strongly advocate that we start small… If it demonstrates and achieves benefits, then that is the 
reason to try a bit more probably.”                                                                    Healthcare Policy Leader 5 
Complexity The potential complexity of pharmacist prescribing particularly in 
relation to diagnostic skills was also raised. 
“If it is left to the pharmacist to make a clinical diagnosis and write a prescription, that to me, is beyond 
the scope, I think.”                                                                                             Patient Safety Advocate 5 
9 
 
Embedding sufficient quality assurance was also highlighted. “The challenge is just to secure the quality that is needed to make this a reality.”  
                                                                                                                           Medical Practice Leader 1 
There was also a concern over conflict with physicians, particularly if 
independently prescribing. 
“The disadvantage would be the conflict... because if you create some kind of independency among 
clinical pharmacist, he might work away from the physicians’ direction.”      Medical Practice Leader 3 
Some interviewees highlighted that the current legislative framework 
could be a barrier to be overcome. 
“You have to change the law which is not easy… How you are going to handle this legal framework? 
How are you going to make it legal for the pharmacists?”                               Healthcare Policy Leader 3 
Another concern was the possibility of overburdening pharmacists. “The other disadvantage is… overburdening the pharmacists with prescribing duties as well as clinical 
duties on the ward.”                                                                                           Patient Safety Advocate 3 
O
ut
er
 se
tti
ng
 Needs and resources Public perceptions of pharmacists, their training, and abilities may hinder 
implementation. 
“Many patients, especially in the Arab region, will tell you “Ah, pharmacist? He just dispense 
medication. I would trust the physician more”.”                                                Academic Leader 2 
Cosmopolitanism The fact that pharmacist prescribing had been successfully implemented 
in other countries could facilitate implementation in Qatar. 
“You have to connect them with other experience or to be affiliated with another organisation whom 
they have the same program for example prescribing in Canada, USA, UK...”  
                                                                                                                           Patient Safety Advocate 1 
In
ne
r 
se
tti
ng
 
Networks and 
Communications 
Interviewees highlighted that health professionals working in hospitals 
were more aware of pharmacists’ clinical roles. 
“Talking about physicians and nurses because they are in a daily contact with the pharmacists, they are 
aware of the pharmacist’s role especially when we say in the hospitals… But talking about maybe 
community, I think no.”                     Academic Leader 3 
Culture There were mixed views relating to organisational culture within Qatar in 
relation to embracing change. 
“You will always get people who embrace the change very, very quickly and you always get people who 
are really kind of slow to adopt the change.”                                                      Nursing Practice Leader 1 
Implementation climate Tension for change Interviewees perceived several positive drivers 
for change such as the lack of physicians. 
“With the increased costs of healthcare and shortage of healthcare providers including physicians of 
course, there is a need to widen the scope of prescribing.”                 Healthcare Policy Leader 2 
Compatibility Another driver was the quality of pharmacy 
education in Qatar. 
“I think you have probably got more chances of getting pharmacists prescribing than nurses. There is a 
very strong academic programme for pharmacists in Qatar…”                Nursing Practice Leader 1 
Readiness for 
implementation 
Leadership engagement There are currently discussions on extending 
pharmacist roles. 
“For my end, I have no objection to it and I am already pushing it ahead now with a fairly senior 
consultant.”                                                                        Healthcare Policy Leader 4 
C
ha
ra
ct
er
ist
ic
s o
f i
nd
iv
id
ua
ls 
Knowledge and beliefs 
about the innovation 
Many highlighted how the knowledge base of pharmacists could facilitate 
pharmacist prescribing. 
“I think pharmacists certainly from my contacts have a tremendous amount of knowledge. They need to 
be supported in expanding their scope of practice.”                                          Academic Leader 9 
Self-efficacy Many commented on pharmacists’ self-efficacy to prescribe. “Pharmacists perceptions about their own roles and responsibility, maybe about their own self-
confidence, maybe they don’t feel ready.”                                                         Academic Leader 1 
Other personal 
attributes 
Others felt that pharmacists were competent enough to prescribe. “I don’t think our pharmacists are less than these countries where these models occurred especially that 
you always have these tests or requirements to get competence.”                    Healthcare Policy Leader 2 
Interviewees highlighted need for experience in clinical practice prior to 
undertaking prescribing. 
“I would say that they should definitely have at least five years of experience because I think those also 
build your confidence and your skills and you can begin to see patterns in patients.” 
                                                                                                                            Academic Leader 9 
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However, similar to medicine, others believed new pharmacy graduates 
should also be allowed to prescribe. 
“That is like asking for a freshly graduated physician needing to have additional and continuing training 
in order to qualify him/her as safe.”                                                                    Medical Practice Leader 1 
Pr
oc
es
s 
Reflecting and 
evaluating 
They should be monitored very carefully to identify and resolve any 
issues. 
“I think that it has to be carefully monitored… to see how they are, how they are doing… and to make 
sure if you want to improve, how do you improve.”                                          Academic Leader 9 
The need to measure the success and value of pharmacist prescribing was 
also highlighted. 
“We will do it, test it, then we will see the results… What are the pros, the cons, values and [do] we get 
added value or it is a waste.”                                                                               Patient Safety Advocate 1 
Abbreviations: 
CFIR: Consolidated Framework for Implementation Research ; UK: United Kingdom 
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The more dominant themes in terms of the depth of discussion and the number of participants discussing each 175 
were those around the preferred design, relative priority, available resources, and planning. Therefore, these are 176 
described in more details below.  177 
CFIR domain 1: Innovation characteristics 178 
Design quality and packaging  179 
(Defined in the framework as the perceived excellence in how the innovation is bundled, presented, and 180 
assembled) 181 
On discussion of the preferred model of pharmacist prescribing and its implementation, there was an 182 
overwhelming view that it would be best to be more conservative, particularly in the initial stages, prior to 183 
proceeding to a more autonomous model. This was highlighted by all stakeholder groups.  184 
“At the time being, I believe that [collaborative prescribing] will be the foundation for things that we have 185 
then after that we will focus on independent.”     Pharmacy Practice Leader 3 186 
The importance of clearly identifying the need for pharmacist prescribing and targeting therapeutic areas and 187 
patient groups was emphasised.  188 
“I think it is also important to see that there is a need for it. Not just do it in all the areas, no.” 189 
         Academic Leader 1 190 
However, several held contrary views that restricting pharmacist prescribing to specific conditions or medicines 191 
may prevent a holistic medicines review. 192 
“I think it is very hard to limit yourself to one section of the formulary… We don't want to get into a 193 
situation where we see the patients and we will say ‘I can only prescribe this bit’.” 194 
         Nursing Practice Leader 1 195 
There was a wide-ranging discussion on the appropriate settings for implementing pharmacist prescribing. 196 
While it appeared that there was more support for implementation in the hospital sector, there was also potential 197 
for later implementation in other settings, including community pharmacy. 198 
“At the time being, I believe that the hospitals should be the first people to implement it just to establish the 199 
fundamental things then after that we can expand it to PHCC and the community pharmacies.” 200 
         Pharmacy Practice Leader 3 201 
There was overwhelming agreement that pharmacist prescribers should undertake specific education and 202 
training prior to prescribing, irrespective of their prior qualifications.  203 
“Train the pharmacists. It is not only training once… It has to be over a long period so that you ensure the 204 
sustainability of the skills and the knowledge they have obtained.”  Academic Leader 2 205 
Supervision was considered to be a key element of the programme to allow assessment of prescribing in practice 206 
and attainment of the required competence.  207 
12 
 
“I think a period of supervised practice would be helpful. So, I think finding a medical colleague who is 208 
really supportive that can kind of support the pharmacist through the process.” 209 
         Nursing Practice Leader 1 210 
CFIR domain 3: Inner setting 211 
Implementation climate: Relative priority  212 
(Individuals’ shared perception of the importance of the implementation within the organisation) 213 
Developing and implementing pharmacist prescribing was perceived to be a priority in keeping with the aims 214 
and ambitions of Qatar National Vision 2030 and the National Health Strategy.  215 
“The triple aims that are set out in the National Health Strategy I think almost require us to think about 216 
pharmacist prescribing more because a major part of it is about safe care.” 217 
         Healthcare Policy Leader 6 218 
Others noted that while pharmacist prescribing was important, other initiatives were more important to 219 
implement mainly due to the existing models of physician prescribing.  220 
“I cannot say it is priority one because physicians are prescribing, and physicians have been prescribing for 221 
many years.”        Healthcare Policy Leader 6 222 
Readiness for implementation: Available resources  223 
(The level of resources organisational dedicated for implementation and on-going operations including 224 
physical space and time) 225 
Positive comments were received on resources which would be required for implementing pharmacist 226 
prescribing, especially in hospital setting.  227 
“I can only talk about it from a hospital perspective but I have never worked in such well-resourced 228 
environment from a pharmacy perspective. So I think it may just be about reengineering and looking at 229 
different ways of practice.”      Nursing Practice Leader 5 230 
Some interviewees held contrary views, expressing views that additional resources would be required to 231 
implement pharmacist prescribing.  232 
“Right now, I think if I just look at HMC, there is not enough resources to just deliver care. So, I think, with 233 
this, it will be a resource intense effort.”     Patient Safety Advocate 5 234 
CFIR domain 5: Process 235 
Planning  236 
(The degree to which a scheme or method of behaviour and tasks for implementing an innovation are 237 
developed in advance, and the quality of those schemes or methods) 238 
In relation to planning for the implementation, one theme which emerged very strongly was the need to engage 239 
with other stakeholder groups to eliminate specific barriers such as resistance. 240 
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“I would then be looking at a stakeholder consultation to say this is what we believe from all the review 241 
work that we have done, what are the issues for the various stakeholders.” 242 
         Nursing Practice Leader 4 243 
Aspects of governance were also considered key to successful implementation, by clearly describing the 244 
prescribing framework and limits of prescribing.  245 
“I would set up some sort of clear governance framework for it and so it is very clear at which point 246 
decisions are made and who is responsible and accountable for them.” 247 
         Nursing Practice Leader 4 248 
Many also discussed the requirement for business case planning, highlighting the weaknesses of the current 249 
system and the likely benefits to be gained from allowing pharmacists in Qatar to prescribe.  250 
“You have to submit a good proposal showing the strengths and weaknesses, the SWOT [strengths, 251 
weaknesses, opportunities and threats] analysis and you should show them of course that this would be 252 
good.”        Healthcare Policy Leader 2 253 
Engaging: Key stakeholders  254 
(Individuals from within the organisation that are directly impacted by the innovation, e.g., staff responsible 255 
for making referrals to a new program or using a new work process) 256 
The need to consult and engage with wide-ranging groups of stakeholders was evident across all interviews.  257 
“It is much easier to achieve change if you have everybody engaged and they will be more agreeable to a 258 
change because it is not being a change applied to them, it is applied with them.” 259 
         Patient Safety Advocate 3 260 
Given that patients were at the centre of healthcare and the prescribing process, it was essential that their views 261 
were taken into account.  262 
“My advice is to involve the patients as early as possible in the process of planning so even if they didn’t 263 
accept it, you will know why.”      Pharmacy Practice Leader 5 264 
Policy makers across many health institutions in Qatar were also considered vital to the implementation process.  265 
“I am quite positive that healthcare policy makers need to be on board. You need to get their buy-in to be 266 
able to promote it.”       Academic Leader 1 267 
Support from pharmacy leaders was also considered crucial, with interviewees discussing the need for 268 
appropriate workload and balance.  269 
“Say you have the staff already committed to do their own work, you need to give them protected time [to 270 
prescribe] and here you need the leaders to be involved.”   Pharmacy Practice Leader 5 271 
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Academics were highlighted as being key to the implementation of pharmacist prescribing particularly in 272 
relation to education and training, and to ensuring appropriate standards of practice.  273 
“I think for developing the competency or developing the guidelines maybe we will need the academic 274 
people.”        Pharmacy Practice Leader 3 275 
On discussing engagement of the drug industry, many interviewees highlighted their concerns over their 276 
involvement.  277 
“You might want to have a representative as an observer, that is fine. But I don’t think they can actually 278 
have any input because they would be biased.”    Academic Leader 7 279 
Categorisation of themes into facilitators and barriers to pharmacist prescribing implementation are given in 280 
Table 4, illustrating a greater number of facilitators than barriers. Key facilitators were tailoring the model to 281 
Qatar needs and providing additional training to pharmacists prior to allowing them to prescribe while the key 282 
barriers reported include the current legislations in the state the potential initial resistance to this new role by 283 
doctors and the public. 284 
 285 
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Table 4: Themes of facilitators and barriers to the implementation of pharmacist prescribing in Qatar mapped to CFIR domains and constructs 
CFIR Domain CFIR construct Corresponding factors Classification 
(Facilitator/Barrier) 
Innovation 
characteristics 
Innovation source Awareness of non-medical prescribing and especially pharmacist prescribing practice globally Facilitator 
Prescribing not currently within the scope of pharmacy practice in Qatar Barrier 
Establishing the pharmacist-led anticoagulation clinic Facilitator 
Evidence strength and quality Robust and rigorous evidence of effectiveness and safety reported globally Facilitator 
Relative advantage Potential to: 
-Increase pharmacists’ job satisfaction and confidence 
-Reduce doctors’ workload  
-Provide timely and holistic care, increasing patients’ experience and satisfaction 
-Reduce cost of healthcare 
-Improve image of the profession 
-Expand role of pharmacy technicians 
Facilitator 
Adaptability Potential to adapt models of pharmacist prescribing developed and implemented in other countries Facilitator 
Trialability Potential to pilot on a small scale to determine effectiveness Facilitator 
Complexity Lack of pharmacists’ diagnostic skills Barrier  
Need to ensure sufficient quality when prescribing Facilitator/ Barrier 
Potential for conflict with physicians, most notably if an independently prescribing developed and implemented Barrier 
Current legislative framework in Qatar Barrier 
Impact on pharmacists’ workload Barrier 
Design quality and packaging Implementing collaborative prescribing before proceeding to a more autonomous model Facilitator 
Need to prescribe in defined areas of clear need Facilitator 
Preference to initially implement in secondary care prior to extending to other settings  Facilitator 
Requirement to provide additional education and supervised training Facilitator 
Outer setting Needs and resources of those served by the 
organisation 
Public and healthcare professionals’ perceptions of pharmacists’ education, training and practice Barrier 
Cosmopolitan Ability to collaborate with other countries experienced in pharmacist prescribing implementation  Facilitator 
Inner setting Networks and communication 
 
 
Existing communication channels in secondary care Facilitator 
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Im
pl
em
en
ta
tio
n 
cl
im
at
e 
Tension for change Shortage in the number of medical prescribers Facilitator 
Compatibility Quality of academic programme at the College of Pharmacy Facilitator 
Relative priority Goals and ambitions of the National Health Strategy and Qatar National Vison 2030 Facilitator 
Competing priorities Barrier 
Re
ad
in
es
s f
or
 
im
pl
em
en
ta
tio
n 
Leadership engagement Current discussions to extend pharmacists’ clinical activities Facilitator 
Available resources Availability of resources most notably in secondary care settings Facilitator 
Need for additional resources to support implementation Barrier 
Characteristics of 
individuals 
Knowledge and beliefs about the 
innovation 
Current knowledge base of practicing pharmacists Facilitator 
Self-efficacy Pharmacists’ lack of confidence to undertake a prescribing role Barrier 
Other personal attributes Pharmacy practice in Qatar considered as advanced as in Qatar as those countries which have implemented pharmacist 
prescribing 
Facilitator 
Requirement for pharmacist prescribers to have experience in clinical area Facilitator 
Process Planning Engagement of other stakeholder groups to identify potential barriers Facilitator 
Requirement to develop robust governance mechanisms (role definition, prescribing framework, model, etc.) Facilitator 
Engaging: Key stakeholders Early engagement of a wide range of stakeholders (pharmacy leaders, policy makers, patients, other providers, 
academics etc.) 
Facilitator 
Reflecting and evaluating Requirement to plan to monitor prescribing practice regularly Facilitator 
Abbreviations: 
CFIR: Consolidated Framework for Implementation Research ; UK: United Kingdom 
 286 
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Discussion 287 
Interviewees were generally aware of models of pharmacist prescribing in other countries and supported the 288 
development and implementation in Qatar, with many potential benefits highlighted. Key facilitators highlighted 289 
include adopting a more conservative model and providing additional training to pharmacists prior to 290 
commencing prescribing. Main barriers were around the current legislative framework and potential initial 291 
opposition by doctors and the public.  292 
There are some similarities between the findings of this interview study and a recently published systematic 293 
review.7 Focusing specifically on pre-implementation studies, several highlighted that major facilitators 294 
identified pre-implementation included pharmacists’ personal qualities (e.g. their clinical experience, education, 295 
and training) and the perceived benefits of pharmacist prescribing (e.g. improved patient access to care and 296 
better utilisation of pharmacists’ skills).20-22 Studies in the systematic review also identified similar barriers in 297 
pre-implementation studies including concerns over pharmacists’ poor clinical skills in assessment and 298 
diagnosing, which were key issues in relation to independent models of prescribing practice.20-25 These concerns 299 
were reiterated in post-implementation studies and may indicate a misunderstanding of the UK independent 300 
prescribing model which does not actually require the diagnosis to be made by the pharmacist independent 301 
prescriber.3 302 
It is notable that these facilitators and barriers have been identified with groups of non-medical prescribers other 303 
than pharmacists, as highlighted in a published umbrella review.4 Facilitators were non-prescribers’ experience 304 
as health professionals, the application of evidence-based guidelines and treatment protocols, peer support, and 305 
encouragement from medical practitioners and patients. Barriers included the lack of clearly defined roles for 306 
non-medical prescribers, no dedicated time allocated to prescribing activities, other competing tasks, lack of 307 
confidence of some NMPs, and the lack of acceptance of the role by other health professionals and patients.4 308 
Given that none of the studies included in these reviews had adopted CFIR or a similar framework, it is not 309 
surprising that they did not comprehensively report the facilitators and barriers. Using CFIR in the interviews 310 
identified additional facilitators and barriers, which should be considered as developments advance. These 311 
include: tailoring the specific model of pharmacist prescribing to the needs of Qatar (innovation characteristics); 312 
educating the public and other healthcare providers on pharmacists’ education and training, and collaborating 313 
with other countries that have implemented pharmacist prescribing (outer setting); aligning more to the goals 314 
and ambitions of the health setting in Qatar, and considering more the readiness for implementation in Qatar 315 
(inner setting); enhancing pharmacists’ confidence to undertake a prescribing role (characteristics of 316 
individuals); and developing robust governance standards and associated processes, involving a diverse group of 317 
stakeholders in implementation, and evaluation of innovation (process). 318 
These additional facilitators and barriers highlight the benefit of adopting a theoretical framework in research. 319 
Identifying these factors pre-implementation can allow for a more tailored implementation, which will 320 
overcome as many barriers as possible. This is likely to result in more successful and sustained implementation 321 
with better outcomes for patients, professionals and the organisation.9-11 There is, therefore, merit in adopting 322 
CFIR in all subsequent stages of development and implementation of pharmacist prescribing in Qatar, as 323 
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discussed earlier. Such an approach may also be relevant for any other country considering implementation of 324 
pharmacist prescribing.  325 
There are many strengths to this study. First, to the best of our knowledge, this is the first and only study on 326 
pharmacist prescribing which has used a theoretical framework of implementation throughout the research 327 
processes hence represents an original contribution to knowledge. Moreover, a qualitative methodology allowed 328 
the generation of in-depth, rich data allowing detailed description and understanding of perspectives.26 Key 329 
stakeholders in positions of power and influence were recruited which would later enable actual implementation 330 
of pharmacist prescribing. Data saturation was observed across and within all stakeholder groups, hence, the 331 
rigour of the findings and likelihood of implementation increased. The main limitation of this research is that the 332 
data were generated in Qatar hence the findings may lack transferability to other countries in the Middle East 333 
and beyond. However, attention has been paid to describing the research setting, methods, and interviewees to 334 
allow readers to consider likely transferability to their own settings and individuals. 335 
Future research needs to focus on determining the most suitable framework and training needs for pharmacist 336 
prescribing in Qatar. A consensus-based approach, such as the Delphi technique, with a similar group of 337 
stakeholders used in this study could be an appropriate approach since it is particularly useful in developing 338 
policies, supporting governance, and stimulating debate around areas where there is uncertainty or incomplete 339 
evidence.27-30 340 
 341 
Conclusion 342 
This qualitative study of key stakeholders in Qatar has demonstrated the potential for pharmacist prescribing to 343 
be developed and implemented in Qatar. Using CFIR pre-implementation has identified key facilitators and 344 
barriers which can be considered as part of action planning, most notably defining models of prescribing 345 
suitable for Qatar, within a governance framework of education, training and accreditation.  346 
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